## **NECTAR LIFESCIENCES LIMITED**



Regd.Office:Vill.Saidpura,Tehsil Derabassi,Distt.Mohali,(Punjab), Corporate Identification Number: L24232PB1995PLC016664

Tel. +91-17 62-30 8000, Fax +91-17 62-30 8135, Email: sunderlal@neclife.com, Website: www.neclife.com (Rs in Lacs)

Part I - Financial Results for the Quarter and the year ended 31.03.2015

S.	PARTICULARS	Quarter ended	Quarter ended	Quarter ended	Year ended	Year ended	Year ended	Year ended
No		31-03-15	31-12-14	31-03-14	31-03-15	31-03-14	31-03-15	31-03-14
		Audited	Unaudited	Audited	Audited	Audited	Audited	Audited
		(Stand-alone)	(Stand-alone)	(Stand-alone)	(Stand-alone)	(Stand-alone)	(Consolidated)	(Consolidated)
1.	Income from Operations							
	(a) Gross Sales	45164.55	47147.37	48218.07	174638.61	170818.37	174638.61	170818.37
	Less : Excise Duty	2818.70	2735.69	2177.98	10349.72	7041.45	10349.72	7041.45
	Net Sales	42345.85	44411.68	46040.09	164288.89	163776.92	164288.89	163776.92
	(b) Other Operating Income	13.82	32.29	34.07	75.30	54.29	75.30	54.29
	Total Income from Operations (net)	42359.67	44443.97	46074.16	164364.19	163831.21	164364.19	163831.21
2.	Expenses							
	(a) Cost of Materials consumed	33097.02	29783.1	36725.71	112990.38	117267.14	112990.38	117267.14
	(b) Purchase of Stock in Trade	282.30	1528.22	147.16	3960.61	3982.32	3960.61	3982.32
	(c) Changes in inventories of finished goods, work-in-progress	(3898.49)	178.79	(2590.51)	(2817.56)	(5781.06)	(2817.56)	(5781.06)
	and stock-in-trade							
	(d) Employee benefits expense	1918.47	1501.69	1173.69	6270.67	5132.87	6270.67	5132.87
	(e) Depreciation and amortisation expense	1938.14	1907.31	2076.06	7656.43	8418.57	7656.43	8418.57
	(f) Other expenses	5372.40	4154.93	3143.83	17269.38	14353.11	17269.38	14353.11
	Total Expenses	38709.84	39054.04	40675.94	145329.91	143372.95	145329.91	143372.95
3.	Profit from Operations before Other Income, finance							
	costs and exceptional Items (1-2)	3649.83	5389.93	5398.22	19034.28	20458.26	19034.28	20458.26
4.	Other Income	1281.62	221.72	90.45	1999.88	1162.75	1999.88	1162.75
5.	Profit before finance costs and exceptional Items (3+4)	4931.45	5611.65	5488.67	21034.16	21621.01	21034.16	21621.01
6.	Finance costs	2687.66	3482.54	3297.13	12558.79	13798.74	12558.79	13798.74
7.	Profit after finance costs but before exceptional Items (5-6)	2243.79	2129.11	2191.54	8475.37	7822.27	8475.37	7822.27
8.	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00	0.00
9.	Profit from ordinary activities before tax (7+8)	2243.79	2129.11	2191.54	8475.37	7822.27	8475.37	7822.27
10.	Tax Expense	572.76	440.58	321.88	1848.98	1614.28	1848.98	1614.28
11.	Net Profit from ordinary activities after tax (9-10)	1671.03	1688.53	1869.66	6626.39	6207.99	6626.39	6207.99
12.	Extraordinary Item (net of tax expense)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
13.	Net Profit for the period (11-12)	1671.03	1688.53	1869.66	6626.39	6207.99	6626.39	6207.99
14.	Paid up Equity Share Capital (Face Value per share : Re.1/-)	2242.61	2242.61	2242.61	2242.61	2242.61	2242.61	2242.61
15.	Reserves excluding Revaluation Reserves				93,552.29	90,463.57	93,552.29	90,463.57
16.i	Earnings per Share (EPS) (before extraordinary items)							
	a) Basic	0.75	0.75	0.83	2.95	2.77	2.95	2.77
	b) Diluted	0.75	0.75	0.83	2.95	2.77	2.95	2.77
16.ii	Earnings per Share (EPS) (after extraordinary items)							
	a) Basic	0.75	0.75	0.83	2.95	2.77	2.95	2.77
	b) Diluted	0.75	0.75	0.83	2.95	2.77	2.95	2.77

Ī	Part II	Select Inform	nation for the Qu	arter and Year	Ended 31.03.20	)15			
Α	Particulars of shareholding								
1.	Public Shareholding								
	- Number of Shares	124,792,970	124,792,970	124792970	124,792,970	124792970	124,792,970	124792970	
	- Percentage of Shareholding	55.65	55.65	55.65	55.65	55.65	55.65	55.65	
2.	Promoters and Promoter Group Shareholding								
	a) Pledged/Encumbered								
	- Number of Shares	55,555,600	55,555,600	0	55,555,600	0	55,555,600	0	
	- Percentage of Shares ( as a % of the total shareholding of	55.85	55.85	0.00	55.85	0.00	55.85	0.00	
	promoter and promoter group)								
	- Percentage of Shares ( as a % of the total share capital of	24.77	24.77	0.00	24.77	0.00	24.77	0.00	
	the company								
	b) Non-encumbered								
	- Number of Shares	43,912,400	43,912,400	99468000	43,912,400	99468000	43,912,400	99468000	
	- Percentage of Shares ( as a % of the total shareholding of	44.15	44.15	100.00	44.15	100.00	44.15	100.00	
	promoter and promoter group)								
	- Percentage of Shares ( as a % of the total share capital of	19.58	19.58	44.35	19.58	44.35	19.58	44.35	
	the company								
В	Investor Complaints			3 Ma	Nonths ended 31.03.2015				
	Pending at the beginning of Quarter				0				
	Received During the Quarter	12							
	Disposed Off During the Quarter				12				
	Pending at the end of Quarter				0				
	Statement of Assets and Liabilities	(Rs in Lacs)							
					As at	As at	As at	As at	
	PARTICULARS				31-03-15	31-03-14	31-03-15	31-03-14	
	TARRESTAN				Audited	Audited	Audited	Audited	
					(Stand-alone)	(Stand-alone)	(Consolidated)	(Consolidated)	
	SHAREHOLDERS' FUND				2242.61	2242.61	2242.61	2242.64	
	(i) Capital				2242.61	2242.61	2242.61	2242.61	
	(ii) Reserves and Surplus			ŀ	93552.29	90463.57	93552.29	90463.57	
	NON CURRENT LIABILITIES				26552.02	22222.00	26552.02	22222.00	
	(i) Long Term Liabilities				26552.92	22333.80	26552.92	22333.80	
	(ii) Deffered Tax Liability				11019.28	11189.31	11019.28	11189.31	
	(ii) Other Long Term Liabilities				1518.72	80.75	1518.72	80.75	
	(iii) Long Term Provisions				601.13	489.99	601.13	489.99	
	CURRENT LIABILITIES				F0F00 = 0	F7004.55	=0=00 =0	==00.4.50	
	(i) Short Term Borrowings				59529.78	57984.20	59529.78	57984.20	
	(ii) Trade Payables				45557.72	44006.09	45557.72	44006.09	
	(iii) Other Current Liabilities				9050.00	8671.49	9050.00	8671.49	
	(iv) Short Term Provisions		_		1422.15	1944.84	1422.15	1944.84	
			Te	otal	251,046.60	239,406.65	251,046.60	239,406.65	

NON CURRENT ASSETS					
(i) Fixed Assets (Incl CWIP)		102504.37	106980.66	102504.37	106980.66
(ii) Non Current Investments		5.01	5.01	5.01	5.01
(iii) Long Term Loans & Advances		8044.27	8686.72	8044.27	8686.72
(iv) Other Non Current Assets		3591.24	0.75	3591.24	0.75
CURRENT ASSETS					
(i) Current Investments		43.51	31.36	43.51	31.36
(ii) Inventories		79097.46	75842.67	79097.46	75842.67
(iii) Trade Receivables		44649.64	37664.86	44649.64	37664.86
(iv) Cash & Bank Balances		3338.20	997.77	3338.20	997.77
(v) Short Term Loans & Advances		8143.15	6582.90	8143.15	6582.90
(vi) Other Current Assets		1629.75	2613.96	1629.75	2613.96
	Total	251,046.60	239,406.65	251,046.60	239,406.65

## Notes:

- 1. The above financial results were reviewed by Audit Committee on 28.05.2015 and approved by the Board in its meeting held on 29.05.2015 and further Audited by the Statutory Auditors of the Company.
- 2. The company is exclusively in the pharmaceutical business segment.
- 3. The Board of Directors has recommended the Final Dividend of Re. 0.10/- per equity share (10% on the face value of Re. 1/- per equity share) for the financial year 2014-15, subject to the approval of Members a their Annual General Meeting.
- 4. Previous year figures have been regrouped and reclassified wherever necessary to make them comparable with current period.
- 5. The figures of the last quarter for the current year and for the previous year are the balancing figures between the audited figure in respect of the full financial year ended 31st March and the unaudited published year to date figures upto the third quarter ended 31st December which was subject to limited review
- 6. Pursuant to the enactment of Companies Act 2013, the company has applied the estimated useful lives as specified in Schedule II/Accounting Standard issued by The Institute of Chartered Accountants of India. Accordingly, the unamortised carrying value is being depreciated/amortised over the revised / remaining useful life. The written down value of Fixed Assets whose lives have expired as at 1st April 2014, (net of deferred tax) has been deducted from the Retained Earnings.

By Order of the Board of Directors of Nectar Lifesciences Limited

Sd/-

Dated: 29.05.2015 Place: Chandigarh (Dinesh Dua)

Chief Executive Officer & Director